Novartis swallows biotech company Morphosys for 2.7 billion euros. Company boss Vasant Narasimhan is particularly interested in its great hope, Pelabresib - the cancer drug could become a blockbuster.
With the acquisition, Novartis secures access to the company's greatest hope, the drug pelabresIB for the treatment of myelofibrosis - a rare malignant disease of the bone marrow. To complete the deal, the necessary antitrust approvals are still required as well as the achievement of a minimum acceptance rate of at least 65 percent of Morphsys shares.